Prediction: This Biotech Stock Will Outperform Nvidia in the Second Half of the YearThe Motley Fool • 09/05/24
Viking Surges 342% in the Past Year: How Should You Play the Stock?Zacks Investment Research • 09/03/24
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive LandscapeSeeking Alpha • 08/30/24
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug RaceInvestors Business Daily • 08/29/24
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare ConferencePRNewsWire • 08/28/24
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts sayMarket Watch • 08/26/24
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?The Motley Fool • 08/26/24
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.The Motley Fool • 08/02/24
The Bull Case for Viking Therapeutics Just Got Even Stronger. Here's Why You Should Buy It.The Motley Fool • 07/29/24
Why Viking's Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk StocksInvestopedia • 07/25/24